<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncologist</journal-id><journal-id journal-id-type="iso-abbrev">Oncologist</journal-id><journal-id journal-id-type="pmc-domain-id">1643</journal-id><journal-id journal-id-type="pmc-domain">oncologist</journal-id><journal-id journal-id-type="publisher-id">oncolo</journal-id><journal-title-group><journal-title>The Oncologist</journal-title></journal-title-group><issn pub-type="ppub">1083-7159</issn><issn pub-type="epub">1549-490X</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11299933</article-id><article-id pub-id-type="pmcid-ver">PMC11299933.1</article-id><article-id pub-id-type="pmcaid">11299933</article-id><article-id pub-id-type="pmcaiid">11299933</article-id><article-id pub-id-type="pmid">38630540</article-id><article-id pub-id-type="doi">10.1093/oncolo/oyae072</article-id><article-id pub-id-type="publisher-id">oyae072</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Genitourinary Cancer</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00010</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>Oncolo/6</subject></subj-group></article-categories><title-group><article-title>Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8700-9312</contrib-id><name name-style="western"><surname>Saad</surname><given-names initials="E">Eddy</given-names></name><aff>
<institution>Dana-Farber Cancer Institute</institution>, <addr-line>Boston, MA</addr-line>, <country country="US">United States</country></aff><xref rid="fn-0001" ref-type="author-notes"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4085-6415</contrib-id><name name-style="western"><surname>Gebrael</surname><given-names initials="G">Georges</given-names></name><aff>
<institution>Huntsman Cancer Institute, University of Utah</institution>, <addr-line>Salt Lake City, UT</addr-line>, <country country="US">United States</country></aff><xref rid="fn-0001" ref-type="author-notes"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Semaan</surname><given-names initials="K">Karl</given-names></name><aff>
<institution>Dana-Farber Cancer Institute</institution>, <addr-line>Boston, MA</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Eid</surname><given-names initials="M">Marc</given-names></name><aff>
<institution>Dana-Farber Cancer Institute</institution>, <addr-line>Boston, MA</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saliby</surname><given-names initials="RM">Ren&#233;e Maria</given-names></name><aff>
<institution>Dana-Farber Cancer Institute</institution>, <addr-line>Boston, MA</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Labaki</surname><given-names initials="C">Chris</given-names></name><aff>
<institution>Dana-Farber Cancer Institute</institution>, <addr-line>Boston, MA</addr-line>, <country country="US">United States</country></aff><aff>
<institution>Beth Israel Deaconess Medical Center</institution>, <addr-line>Boston, MA</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sayegh</surname><given-names initials="N">Nicolas</given-names></name><aff>
<institution>Huntsman Cancer Institute, University of Utah</institution>, <addr-line>Salt Lake City, UT</addr-line>, <country country="US">United States</country></aff><aff>
<institution>UT Southwestern Medical Center</institution>, <addr-line>Dallas, TX</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7655-1405</contrib-id><name name-style="western"><surname>Wells</surname><given-names initials="JC">J Connor</given-names></name><aff>
<institution>BC Cancer Agency</institution>, <addr-line>Vancouver</addr-line>, <country country="CA">Canada</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Takemura</surname><given-names initials="K">Kosuke</given-names></name><aff>Cancer Institute Hospital, <institution>Japanese Foundation for Cancer Research</institution>, <addr-line>Tokyo</addr-line>, <country country="JP">Japan</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ernst</surname><given-names initials="MS">Matthew Scott</given-names></name><aff>
<institution>Tom Baker Cancer Centre, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lemelin</surname><given-names initials="A">Audreylie</given-names></name><aff>
<institution>Tom Baker Cancer Centre, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Basappa</surname><given-names initials="NS">Naveen S</given-names></name><aff>
<institution>Cross Cancer Institute, University of Alberta</institution>, <addr-line>Edmonton, AB</addr-line>, <country country="CA">Canada</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wood</surname><given-names initials="LA">Lori A</given-names></name><aff>
<institution>Queen Elizabeth II Health Sciences Centre, Dalhousie University</institution>, <addr-line>Halifax, NS</addr-line>, <country country="CA">Canada</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Powles</surname><given-names initials="T">Thomas</given-names></name><aff>
<institution>Experimental Cancer Medicine Centre, Barts Cancer Institute, St. Bartholomew&#8217;s Hospital, Queen Mary University of London</institution>, <addr-line>London</addr-line>, <country country="GB">United Kingdom</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ernst</surname><given-names initials="DS">D Scott</given-names></name><aff>
<institution>Department of Oncology, Western University</institution>, <addr-line>London, ON</addr-line>, <country country="CA">Canada</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lalani</surname><given-names initials="AKA">Aly-Khan A</given-names></name><aff>
<institution>Juravinski Cancer Centre, McMaster University</institution>, <addr-line>Hamilton, ON</addr-line>, <country country="CA">Canada</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1076-0428</contrib-id><name name-style="western"><surname>Agarwal</surname><given-names initials="N">Neeraj</given-names></name><aff>
<institution>Huntsman Cancer Institute, University of Utah</institution>, <addr-line>Salt Lake City, UT</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xie</surname><given-names initials="W">Wanling</given-names></name><aff>
<institution>Dana-Farber Cancer Institute</institution>, <addr-line>Boston, MA</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Heng</surname><given-names initials="DYC">Daniel Y C</given-names></name><aff>
<institution>Tom Baker Cancer Centre, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country></aff><xref rid="fn-0001" ref-type="author-notes"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9201-3217</contrib-id><name name-style="western"><surname>Choueiri</surname><given-names initials="TK">Toni K</given-names></name><xref rid="c1" ref-type="corresp"/><aff>
<institution>Dana-Farber Cancer Institute</institution>, <addr-line>Boston, MA</addr-line>, <country country="US">United States</country></aff><xref rid="fn-0001" ref-type="author-notes"/></contrib></contrib-group><author-notes><corresp id="c1">Corresponding author: Toni K. Choueiri, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA (<email>toni_choueiri@dfci.harvard.edu</email>).</corresp><fn id="fn-0001"><p>Eddy Saad, Georges Gebrael, Daniel Y.C. Heng and Toni K. Choueiri Contributed equally.</p></fn></author-notes><pub-date pub-type="collection"><month>8</month><year>2024</year></pub-date><pub-date pub-type="epub" iso-8601-date="2024-04-17"><day>17</day><month>4</month><year>2024</year></pub-date><volume>29</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">468188</issue-id><fpage>699</fpage><lpage>706</lpage><history><date date-type="received"><day>04</day><month>3</month><year>2024</year></date><date date-type="accepted"><day>18</day><month>3</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>04</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>06</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-28 15:25:17.653"><day>28</day><month>08</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024. Published by Oxford University Press.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#8212;for further information please contact journals.permissions@oup.com.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="oyae072.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oyae072.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Current tobacco smoking is independently associated with decreased overall survival (OS) among patients with metastatic renal cell carcinoma (mRCC) treated with targeted monotherapy (VEGF-TKI). Herein, we assess the influence of smoking status on the outcomes of patients with mRCC treated with the current first-line standard of care of immune checkpoint inhibitor (ICI)-based regimens.</p></sec><sec id="s2"><title>Materials and Methods</title><p>Real-world data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) were collected retrospectively. Patients with mRCC who received either dual ICI therapy or ICI with VEGF-TKI in the first-line setting were included and were categorized as current, former, or nonsmokers. The primary outcomes were OS, time to treatment failure (TTF), and objective response rate (ORR). OS and TTF were compared between groups using the log-rank test and multivariable Cox regression models. ORR was assessed between the 3 groups using a multivariable logistic regression model.</p></sec><sec id="s3"><title>Results</title><p>A total of 989 eligible patients were included in the analysis, with 438 (44.3%) nonsmokers, 415 (42%) former, and 136 (13.7%) current smokers. Former smokers were older and included more males, while other baseline characteristics were comparable between groups. Median follow-up for OS was 21.2 months. In the univariate analysis, a significant difference between groups was observed for OS (<italic toggle="yes">P</italic>&#8197;=&#8197;.027) but not for TTF (<italic toggle="yes">P</italic>&#8197;=&#8197;.9), with current smokers having the worse 2-year OS rate (62.8% vs 70.8% and 73.1% in never and former smokers, respectively). After adjusting for potential confounders, no significant differences in OS or TTF were observed among the 3 groups. However, former smokers demonstrated a higher ORR compared to never smokers (OR 1.45, <italic toggle="yes">P</italic>&#8197;=&#8197;.02).</p></sec><sec id="s4"><title>Conclusion</title><p>Smoking status does not appear to independently influence the clinical outcomes to first-line ICI-based regimens in patients with mRCC. Nonetheless, patient counseling on tobacco cessation remains a crucial aspect of managing patients with mRCC, as it significantly reduces all-cause mortality.</p></sec></abstract><abstract abstract-type="teaser"><p>This article assesses the influence of smoking status on the outcomes of patients with metastatic renal cell carcinoma treated with the current first-line standard of care of immune checkpoint inhibitor-based regimens.</p></abstract><kwd-group><kwd>kidney cancer</kwd><kwd>renal cell carcinoma</kwd><kwd>immune checkpoint inhibitors</kwd><kwd>immunotherapy</kwd><kwd>smoking</kwd></kwd-group><counts><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text position="float" orientation="portrait"><caption><title>Implications for Practice</title></caption><p>Patients with metastatic renal cell carcinoma who currently smoke have worse overall survival compared to never or former smokers, following treatment with immune checkpoint inhibitors (ICIs). However, after adjusting for potential confounders, smoking did not seem to independently affect the efficacy of ICI-based regimens. Smoking cessation should still be advised as it has been shown to decrease all-cause overall mortality.</p></boxed-text><sec id="s5"><title>Introduction</title><p>Smoking tobacco products has been consistently linked with an increased risk of developing renal cell carcinoma (RCC). The association between smoking and RCC seems to be dose-dependent, with heavier smoking resulting in a higher risk of RCC. Notably, smoking cessation reduces the risk of RCC, with long-term cessation leading to substantial benefits.<sup><xref rid="CIT0001" ref-type="bibr">1</xref></sup> Moreover, active smoking negatively impacts the efficacy of targeted therapies, which constitute an essential component of standard-of-care systemic regimens used for the treatment of metastatic RCC (mRCC).<sup><xref rid="CIT0002" ref-type="bibr">2</xref></sup> Currently, immune checkpoint inhibitor (ICI)-based combinations represent the recommended first-line regimens for the treatment of mRCC. However, the impact of smoking status on the response to these therapies has not been clearly evaluated in mRCC.</p><p>In non&#8211;small cell lung cancer (NSCLC), it is hypothesized that carcinogens present in cigarettes can induce mutations that result in a greater number of neoantigens, thereby enhancing immunogenicity and response to immunotherapy.<sup><xref rid="CIT0003" ref-type="bibr">3</xref></sup> In lung adenocarcinoma, 80% of patients with high tumor mutation burden (TMB) had a recent smoking history, compared to just 19% of those with low TMB.<sup><xref rid="CIT0004" ref-type="bibr">4</xref></sup> In line with these findings, patients with NSCLC who had a history of smoking and were treated with first-line pembrolizumab had a significantly longer overall survival (OS) when compared to those who had never smoked.<sup><xref rid="CIT0005" ref-type="bibr">5</xref></sup> Similarly, in the context of NSCLC and response to pembrolizumab, tumors displaying a smoking-associated molecular signature showed better clinical outcomes in response to treatment.<sup><xref rid="CIT0006" ref-type="bibr">6</xref></sup> However, the same mutational smoking signature affects the tumor immune microenvironment differently depending on the anatomical location, leading to either immunosuppression or inflammation.<sup><xref rid="CIT0007" ref-type="bibr">7</xref></sup> This difference underscores the importance of studying the effect of smoking on the effectiveness of immunotherapy in different types of cancer. Thus, we aimed to investigate the impact of smoking status on survival outcomes and treatment response in patients with mRCC treated with first-line ICI-based combination therapies in a real-world setting.</p></sec><sec sec-type="materials" id="s6"><title>Materials and methods</title><sec id="s7"><title>Study design</title><p>This is a retrospective study using data from the International mRCC Database Consortium (IMDC).<sup><xref rid="CIT0008" ref-type="bibr">8</xref></sup> IRB approval was obtained in each of the participating research centers.</p></sec><sec id="s8"><title>Patient selection</title><p>We collected data from patients with mRCC who received FDA-approved ICI-based therapy at first line, including anti-programmed death 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) with targeted therapy and anti-PD-1 with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) combinations. Exclusion criteria included patients who received targeted monotherapy at first line and patients for whom smoking status at the time of diagnosis was missing.</p></sec><sec id="s9"><title>Smoking status</title><p>Smoking status was obtained from the medical charts or screening forms at the time of diagnosis. Accordingly, patients were classified into 3 categories: never smokers, former smokers, and current smokers.<sup><xref rid="CIT0002" ref-type="bibr">2</xref></sup> Never smokers were defined as patients who have smoked less than 100 cigarettes until the time of diagnosis, former smokers refer to patients who smoked &#8805;100 cigarettes and stopped smoking at least a year before the time of diagnosis, while current smokers refer to patients who smoked &#8805;100 cigarettes including at least one cigarette within the year preceding their diagnosis.</p></sec><sec id="s10"><title>Statistical analysis</title><p>Patient characteristics were compared between the 3 smoking status groups using the chi-squared test for categorical variables and the Kruskal-Wallis test for continuous variables, with a post hoc Dunn&#8217;s pairwise comparison.</p><p>Overall survival was defined as the time between the initiation of first-line treatment and death, with censuring on the date of the last follow-up. Time to treatment failure (TTF) was defined as the time between the initiation and cessation of first-line treatment or censored on the date of last follow-up for those who remained on therapy. Median follow-up was calculated using the reverse Kaplan-Meier method. Objective response was defined as either a partial or a complete response according to the RECIST1.1 criteria.<sup><xref rid="CIT0009" ref-type="bibr">9</xref></sup></p><p>OS and TTF were compared between never, former, and current smokers using the log-rank test as well as a multivariable Cox regression model while adjusting for the following variables: IMDC risk group, age at the start of first-line therapy, sex, BMI, RCC histology (clear cell RCC vs non&#8211;clear cell RCC), presence of a sarcomatoid and/or rhabdoid differentiation, presence of any of brain, bone or liver metastases, year of start of first-line therapy and time between diagnosis and start of first-line therapy. Objective response rate (ORR) was compared between the 3 groups using a multivariable logistic regression model while adjusting for the same covariates. Missing values were included as a &#8220;missing&#8221; category to retain patients in the multivariable models.</p><p>Significance threshold was set at 0.05 (2-sided). All analyses were performed using R (version 4.3.0) on RStudio (version 2023.03.0.386).</p></sec></sec><sec id="s11"><title>Results</title><p>A total of 989 patients with mRCC were eligible and were included in this study (<xref rid="F1" ref-type="fig">Figure 1</xref>). Overall, 711 (71.9%) were males and 592 (59.7%) were White. Regarding smoking status, 438 patients (44.3%) were never smokers, 415 (42.0%) were former smokers, and 136 (13.7%) were current smokers at mRCC diagnosis. The median follow-up for OS was 21.2 months.</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>CONSORT flow diagram showing the patients included in the study.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="oyae072_fig1.jpg"/></fig><p>There were no differences in terms of clinical, demographic, and pathologic features between the 3 smoking status groups, with the exception of sex and age at initiation of first-line therapy (<xref rid="T1" ref-type="table">Table 1</xref>). Overall, former smokers included a higher percentage of males compared to never smokers (76.6% vs 66.7% <italic toggle="yes">P</italic>&#8197;=&#8197;.002 [post hoc pairwise comparison]) and were older than current smokers (median 64.7 vs 62.4 years <italic toggle="yes">P</italic>&#8197;=&#8197;.01 [post hoc pairwise comparison]).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><p>Clinical characteristics of patients in the different smoking subgroups.</p></caption><table frame="hsides" rules="groups" width="100%" border="1"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Never smokers<break/>(<italic toggle="yes">N</italic>&#8197;=&#8197;438)</th><th align="left" rowspan="1" colspan="1">Former smokers<break/>(<italic toggle="yes">N</italic>&#8197;=&#8197;415)</th><th align="left" rowspan="1" colspan="1">Current smokers<break/>(<italic toggle="yes">N</italic>&#8197;=&#8197;136)</th><th align="left" rowspan="1" colspan="1">Overall<break/>(<italic toggle="yes">N</italic>&#8197;=&#8197;989)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Sex</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Female</td><td align="left" rowspan="1" colspan="1">146 (33.3%)</td><td align="left" rowspan="1" colspan="1">97 (23.4%)</td><td align="left" rowspan="1" colspan="1">35 (25.7%)</td><td align="left" rowspan="1" colspan="1">278 (28.1%)</td><td align="left" rowspan="2" colspan="1">
<bold>0.004</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Male</td><td align="left" rowspan="1" colspan="1">292 (66.7%)</td><td align="left" rowspan="1" colspan="1">318 (76.6%)</td><td align="left" rowspan="1" colspan="1">101 (74.3%)</td><td align="left" rowspan="1" colspan="1">711 (71.9%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Nephrectomy</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">142 (32.4%)</td><td align="left" rowspan="1" colspan="1">140 (33.7%)</td><td align="left" rowspan="1" colspan="1">45 (33.1%)</td><td align="left" rowspan="1" colspan="1">327 (33.1%)</td><td align="left" rowspan="2" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">296 (67.6%)</td><td align="left" rowspan="1" colspan="1">275 (66.3%)</td><td align="left" rowspan="1" colspan="1">91 (66.9%)</td><td align="left" rowspan="1" colspan="1">662 (66.9%)</td></tr><tr><td align="left" colspan="6" rowspan="1">1L ICI combination</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Avelumab&#8197;+&#8197;axitinib</td><td align="left" rowspan="1" colspan="1">13 (3.0%)</td><td align="left" rowspan="1" colspan="1">22 (5.3%)</td><td align="left" rowspan="1" colspan="1">4 (2.9%)</td><td align="left" rowspan="1" colspan="1">39 (3.9%)</td><td align="left" rowspan="5" colspan="1">0.13</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Nivolumab&#8197;+&#8197;cabozantinib</td><td align="left" rowspan="1" colspan="1">25 (5.7%)</td><td align="left" rowspan="1" colspan="1">12 (2.9%)</td><td align="left" rowspan="1" colspan="1">4 (2.9%)</td><td align="left" rowspan="1" colspan="1">41 (4.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Nivolumab&#8197;+&#8197;ipilimumab</td><td align="left" rowspan="1" colspan="1">297 (67.8%)</td><td align="left" rowspan="1" colspan="1">289 (69.6%)</td><td align="left" rowspan="1" colspan="1">90 (66.2%)</td><td align="left" rowspan="1" colspan="1">676 (68.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Pembrolizumab&#8197;+&#8197;axitinib</td><td align="left" rowspan="1" colspan="1">94 (21.5%)</td><td align="left" rowspan="1" colspan="1">79 (19.0%)</td><td align="left" rowspan="1" colspan="1">31 (22.8%)</td><td align="left" rowspan="1" colspan="1">204 (20.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Pembrolizumab&#8197;+&#8197;lenvatinib</td><td align="left" rowspan="1" colspan="1">9 (2.0%)</td><td align="left" rowspan="1" colspan="1">13 (3.1%)</td><td align="left" rowspan="1" colspan="1">7 (5.1%)</td><td align="left" rowspan="1" colspan="1">29 (2.9%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Sarcomatoid/rhabdoid differentiation</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">156 (35.6%)</td><td align="left" rowspan="1" colspan="1">128 (30.8%)</td><td align="left" rowspan="1" colspan="1">40 (29.4%)</td><td align="left" rowspan="1" colspan="1">324 (32.8%)</td><td align="left" rowspan="2" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">85 (19.4%)</td><td align="left" rowspan="1" colspan="1">67 (16.1%)</td><td align="left" rowspan="1" colspan="1">33 (24.3%)</td><td align="left" rowspan="1" colspan="1">185 (18.7%)</td></tr><tr><td align="left" colspan="6" rowspan="1">KPS at 1L start</td></tr><tr><td align="left" rowspan="1" colspan="1">&lt;60</td><td align="left" rowspan="1" colspan="1">25 (5.7%)</td><td align="left" rowspan="1" colspan="1">31 (7.5%)</td><td align="left" rowspan="1" colspan="1">15 (11.0%)</td><td align="left" rowspan="1" colspan="1">71 (7.2%)</td><td align="left" rowspan="5" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;70</td><td align="left" rowspan="1" colspan="1">32 (7.3%)</td><td align="left" rowspan="1" colspan="1">28 (6.7%)</td><td align="left" rowspan="1" colspan="1">12 (8.8%)</td><td align="left" rowspan="1" colspan="1">72 (7.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;80</td><td align="left" rowspan="1" colspan="1">114 (26.0%)</td><td align="left" rowspan="1" colspan="1">111 (26.7%)</td><td align="left" rowspan="1" colspan="1">37 (27.2%)</td><td align="left" rowspan="1" colspan="1">262 (26.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;90</td><td align="left" rowspan="1" colspan="1">65 (14.8%)</td><td align="left" rowspan="1" colspan="1">68 (16.4%)</td><td align="left" rowspan="1" colspan="1">16 (11.8%)</td><td align="left" rowspan="1" colspan="1">149 (15.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;100</td><td align="left" rowspan="1" colspan="1">168 (38.4%)</td><td align="left" rowspan="1" colspan="1">143 (34.5%)</td><td align="left" rowspan="1" colspan="1">50 (36.8%)</td><td align="left" rowspan="1" colspan="1">361 (36.5%)</td></tr><tr><td align="left" colspan="6" rowspan="1">IMDC risk group</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Favorable</td><td align="left" rowspan="1" colspan="1">69 (15.8%)</td><td align="left" rowspan="1" colspan="1">54 (13.0%)</td><td align="left" rowspan="1" colspan="1">17 (12.5%)</td><td align="left" rowspan="1" colspan="1">140 (14.2%)</td><td align="left" rowspan="3" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Intermediate</td><td align="left" rowspan="1" colspan="1">183 (41.8%)</td><td align="left" rowspan="1" colspan="1">184 (44.3%)</td><td align="left" rowspan="1" colspan="1">50 (36.8%)</td><td align="left" rowspan="1" colspan="1">417 (42.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Poor</td><td align="left" rowspan="1" colspan="1">96 (21.9%)</td><td align="left" rowspan="1" colspan="1">92 (22.2%)</td><td align="left" rowspan="1" colspan="1">42 (30.9%)</td><td align="left" rowspan="1" colspan="1">230 (23.3%)</td></tr><tr><td align="left" colspan="6" rowspan="1">&#8805;1 metastatic site</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">81 (18.5%)</td><td align="left" rowspan="1" colspan="1">59 (14.2%)</td><td align="left" rowspan="1" colspan="1">16 (11.8%)</td><td align="left" rowspan="1" colspan="1">156 (15.8%)</td><td align="left" rowspan="2" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">323 (73.7%)</td><td align="left" rowspan="1" colspan="1">306 (73.7%)</td><td align="left" rowspan="1" colspan="1">103 (75.7%)</td><td align="left" rowspan="1" colspan="1">732 (74.0%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Presence of brain, bone, or liver metastases</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">233 (53.2%)</td><td align="left" rowspan="1" colspan="1">213 (51.3%)</td><td align="left" rowspan="1" colspan="1">66 (48.5%)</td><td align="left" rowspan="1" colspan="1">512 (51.8%)</td><td align="left" rowspan="2" colspan="1">0.67</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">204 (46.6%)</td><td align="left" rowspan="1" colspan="1">195 (47.0%)</td><td align="left" rowspan="1" colspan="1">69 (50.7%)</td><td align="left" rowspan="1" colspan="1">468 (47.3%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Clear cell component</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">60 (13.7%)</td><td align="left" rowspan="1" colspan="1">58 (14.0%)</td><td align="left" rowspan="1" colspan="1">16 (11.8%)</td><td align="left" rowspan="1" colspan="1">134 (13.5%)</td><td align="left" rowspan="2" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">329 (75.1%)</td><td align="left" rowspan="1" colspan="1">301 (72.5%)</td><td align="left" rowspan="1" colspan="1">102 (75.0%)</td><td align="left" rowspan="1" colspan="1">732 (74.0%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Year of 1L start</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;From 2012 to 2015</td><td align="left" rowspan="1" colspan="1">17 (3.9%)</td><td align="left" rowspan="1" colspan="1">16 (3.9%)</td><td align="left" rowspan="1" colspan="1">4 (2.9%)</td><td align="left" rowspan="1" colspan="1">37 (3.7%)</td><td align="left" rowspan="3" colspan="1">0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;From 2016 to 2019</td><td align="left" rowspan="1" colspan="1">169 (38.6%)</td><td align="left" rowspan="1" colspan="1">184 (44.3%)</td><td align="left" rowspan="1" colspan="1">61 (44.9%)</td><td align="left" rowspan="1" colspan="1">414 (41.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;After 2020</td><td align="left" rowspan="1" colspan="1">251 (57.3%)</td><td align="left" rowspan="1" colspan="1">214 (51.6%)</td><td align="left" rowspan="1" colspan="1">71 (52.2%)</td><td align="left" rowspan="1" colspan="1">536 (54.2%)</td></tr><tr><td align="left" colspan="6" rowspan="1">BMI group</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Normal weight</td><td align="left" rowspan="1" colspan="1">115 (26.3%)</td><td align="left" rowspan="1" colspan="1">95 (22.9%)</td><td align="left" rowspan="1" colspan="1">33 (24.3%)</td><td align="left" rowspan="1" colspan="1">243 (24.6%)</td><td align="left" rowspan="4" colspan="1">0.88</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Underweight</td><td align="left" rowspan="1" colspan="1">10 (2.3%)</td><td align="left" rowspan="1" colspan="1">6 (1.4%)</td><td align="left" rowspan="1" colspan="1">3 (2.2%)</td><td align="left" rowspan="1" colspan="1">19 (1.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Overweight</td><td align="left" rowspan="1" colspan="1">120 (27.4%)</td><td align="left" rowspan="1" colspan="1">124 (29.9%)</td><td align="left" rowspan="1" colspan="1">44 (32.4%)</td><td align="left" rowspan="1" colspan="1">288 (29.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Obese</td><td align="left" rowspan="1" colspan="1">110 (25.1%)</td><td align="left" rowspan="1" colspan="1">106 (25.5%)</td><td align="left" rowspan="1" colspan="1">34 (25.0%)</td><td align="left" rowspan="1" colspan="1">250 (25.3%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Age at 1L start (years)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Median [IQR]</td><td align="left" rowspan="1" colspan="1">63 [56, 70]</td><td align="left" rowspan="1" colspan="1">65 [57, 70]</td><td align="left" rowspan="1" colspan="1">62 [58, 65]</td><td align="left" rowspan="1" colspan="1">63 [57, 69]</td><td align="left" rowspan="1" colspan="1">
<bold>0.03</bold>
</td></tr><tr><td align="left" colspan="6" rowspan="1">Time from diagnosis to 1L start (years)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Median [IQR]</td><td align="left" rowspan="1" colspan="1">0.53 [0.13, 2.06]</td><td align="left" rowspan="1" colspan="1">0.41 [0.13, 2.26]</td><td align="left" rowspan="1" colspan="1">0.35 [0.11, 2.11]</td><td align="left" rowspan="1" colspan="1">0.47 [0.13, 2.15]</td><td align="left" rowspan="1" colspan="1">0.76</td></tr></tbody></table><table-wrap-foot><fn id="T1Fn1"><p>Bold values denote statistical significance at the <italic toggle="yes">P</italic> &lt; 0.05 level using the chi-squared test for categorical variables and the Kruskal-Wallis test for continuous variables. The total patient count may be affected by missing data.</p></fn><fn id="T1Fn2"><p>Abbreviations: 1L, first-line; ICI, immune checkpoint inhibitors; KPS, Karnofsky Performance Scale; IMDC, International Metastatic renal cell carcinoma Database Consortium; BMI, body mass index; IQR, interquartile range.</p></fn></table-wrap-foot></table-wrap><p>At the time of the analysis, 267 patients (27.0%) had died and 685 (69.3%) had stopped first-line treatment. In a univariate analysis, there was a significant difference in OS among the 3 smoking status subgroups (log-rank test, <italic toggle="yes">P</italic>&#8197;=&#8197;.027), with current smokers displaying the lowest OS rates. The 2-year OS rates were 70.8% (95% CI 65.7-76.2), 73.1% (95% CI 68.2-78.5), and 62.8% (95% CI 54.1-73.0) in never, former, and current smokers, respectively (<xref rid="F2" ref-type="fig">Figure 2</xref>). There was no statistical difference in TTF among the 3 groups in the univariate analysis (log-rank test, <italic toggle="yes">P</italic>&#8197;=&#8197;.9). The median TTF was 7.8 months (95% CI 5.5-9.4) for never smokers, 7.3 months (95% CI 6.2-9.3) for former smokers, and 6.4 months (95% CI 3.1-12.7) for current smokers (<xref rid="F3" ref-type="fig">Figure 3</xref>).</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>Kaplan-Meier curves for overall survival (OS) according to smoking status. Abbreviation: ICI, immune checkpoint inhibitors.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="oyae072_fig2.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p>Kaplan-Meier curves for time to treatment failure (TTF) according to smoking status. Abbreviation: ICI, immune checkpoint inhibitors.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="oyae072_fig3.jpg"/></fig><p>The ORR reached 40.9% (95% CI: 35.9-46.1%) among never smokers, while it was of 48.5% (95% CI: 43.2-53.8%) in former smokers, and 41.7% (95% CI: 32.6-51.3%) in current smokers.</p><p>In the multivariable model, there was no statistically detected difference in OS between either former or current smokers versus never smokers (HR 0.77; 95% CI 0.58-1.01; <italic toggle="yes">P</italic>&#8197;=&#8197;.06 and 1.12; 95% CI 0.79-1.58; <italic toggle="yes">P</italic>&#8197;=&#8197;.54, respectively; <xref rid="T2" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2.</label><caption><p>Multivariable Cox regression model for OS and TTF and multivariable logistic regression for ORR.</p></caption><table frame="hsides" rules="groups" width="100%" border="1"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="3" rowspan="1">OS</th><th align="left" colspan="3" rowspan="1">TTF</th><th align="left" colspan="3" rowspan="1">ORR</th></tr><tr><th align="left" rowspan="1" colspan="1">HR</th><th align="left" rowspan="1" colspan="1">HR 95% CI</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>-value</th><th align="left" rowspan="1" colspan="1">HR</th><th align="left" rowspan="1" colspan="1">HR 95% CI</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>-value</th><th align="left" rowspan="1" colspan="1">OR</th><th align="left" rowspan="1" colspan="1">OR 95% CI</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="10" rowspan="1">Smoking status at diagnosis</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Never smokers</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(ref.)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(ref.)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(ref.)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Former smokers</td><td align="left" rowspan="1" colspan="1">0.77</td><td align="left" rowspan="1" colspan="1">0.58-1.01</td><td align="left" rowspan="1" colspan="1">0.06</td><td align="left" rowspan="1" colspan="1">0.88</td><td align="left" rowspan="1" colspan="1">0.74-1.04</td><td align="left" rowspan="1" colspan="1">0.12</td><td align="left" rowspan="1" colspan="1">1.45</td><td align="left" rowspan="1" colspan="1">1.06-1.98</td><td align="left" rowspan="1" colspan="1">
<bold>0.02</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Current smokers</td><td align="left" rowspan="1" colspan="1">1.12</td><td align="left" rowspan="1" colspan="1">0.79-1.58</td><td align="left" rowspan="1" colspan="1">0.54</td><td align="left" rowspan="1" colspan="1">0.93</td><td align="left" rowspan="1" colspan="1">0.73-1.19</td><td align="left" rowspan="1" colspan="1">0.59</td><td align="left" rowspan="1" colspan="1">1.07</td><td align="left" rowspan="1" colspan="1">0.69-1.68</td><td align="left" rowspan="1" colspan="1">0.76</td></tr><tr><td align="left" colspan="10" rowspan="1">BMI at 1L start</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Normal weight</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(ref.)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(ref.)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(ref.)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Obese</td><td align="left" rowspan="1" colspan="1">1.12</td><td align="left" rowspan="1" colspan="1">0.78-1.62</td><td align="left" rowspan="1" colspan="1">0.54</td><td align="left" rowspan="1" colspan="1">0.83</td><td align="left" rowspan="1" colspan="1">0.66-1.05</td><td align="left" rowspan="1" colspan="1">0.12</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.66-1.51</td><td align="left" rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Overweight</td><td align="left" rowspan="1" colspan="1">1.06</td><td align="left" rowspan="1" colspan="1">0.75-1.49</td><td align="left" rowspan="1" colspan="1">0.76</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">0.74-1.13</td><td align="left" rowspan="1" colspan="1">0.41</td><td align="left" rowspan="1" colspan="1">1.14</td><td align="left" rowspan="1" colspan="1">0.77-1.69</td><td align="left" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Underweight</td><td align="left" rowspan="1" colspan="1">2.16</td><td align="left" rowspan="1" colspan="1">1.02-4.54</td><td align="left" rowspan="1" colspan="1">
<bold>0.043</bold>
</td><td align="left" rowspan="1" colspan="1">2.24</td><td align="left" rowspan="1" colspan="1">1.36-3.67</td><td align="left" rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td align="left" rowspan="1" colspan="1">0.56</td><td align="left" rowspan="1" colspan="1">0.19-1.69</td><td align="left" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" colspan="10" rowspan="1">IMDC group at 1L start</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Favorable</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(ref.)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(ref.)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(ref.)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Intermediate</td><td align="left" rowspan="1" colspan="1">1.59</td><td align="left" rowspan="1" colspan="1">1.00-2.55</td><td align="left" rowspan="1" colspan="1">0.05</td><td align="left" rowspan="1" colspan="1">1.43</td><td align="left" rowspan="1" colspan="1">1.10-1.85</td><td align="left" rowspan="1" colspan="1">
<bold>0.007</bold>
</td><td align="left" rowspan="1" colspan="1">0.57</td><td align="left" rowspan="1" colspan="1">0.36-0.89</td><td align="left" rowspan="1" colspan="1">
<bold>0.01</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Poor</td><td align="left" rowspan="1" colspan="1">3.36</td><td align="left" rowspan="1" colspan="1">2.03-5.58</td><td align="left" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td><td align="left" rowspan="1" colspan="1">1.61</td><td align="left" rowspan="1" colspan="1">1.20-2.18</td><td align="left" rowspan="1" colspan="1">
<bold>0.002</bold>
</td><td align="left" rowspan="1" colspan="1">0.50</td><td align="left" rowspan="1" colspan="1">0.29-0.84</td><td align="left" rowspan="1" colspan="1">
<bold>0.009</bold>
</td></tr><tr><td align="left" colspan="10" rowspan="1">Sex</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Female</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(ref.)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(ref.)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(ref.)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Male</td><td align="left" rowspan="1" colspan="1">0.78</td><td align="left" rowspan="1" colspan="1">0.60-1.02</td><td align="left" rowspan="1" colspan="1">0.073</td><td align="left" rowspan="1" colspan="1">0.86</td><td align="left" rowspan="1" colspan="1">0.73-1.03</td><td align="left" rowspan="1" colspan="1">0.10</td><td align="left" rowspan="1" colspan="1">1.25</td><td align="left" rowspan="1" colspan="1">0.90-1.74</td><td align="left" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">Age at 1L start (years)</td><td align="left" rowspan="1" colspan="1">1.02</td><td align="left" rowspan="1" colspan="1">1.00-1.03</td><td align="left" rowspan="1" colspan="1">
<bold>0.009</bold>
</td><td align="left" rowspan="1" colspan="1">1.01</td><td align="left" rowspan="1" colspan="1">1.00-1.02</td><td align="left" rowspan="1" colspan="1">
<bold>0.04</bold>
</td><td align="left" rowspan="1" colspan="1">0.99</td><td align="left" rowspan="1" colspan="1">0.97-1.00</td><td align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">Brain, bone, or liver metastases</td><td align="left" rowspan="1" colspan="1">1.25</td><td align="left" rowspan="1" colspan="1">0.96-1.63</td><td align="left" rowspan="1" colspan="1">0.091</td><td align="left" rowspan="1" colspan="1">1.06</td><td align="left" rowspan="1" colspan="1">0.90-1.25</td><td align="left" rowspan="1" colspan="1">0.48</td><td align="left" rowspan="1" colspan="1">0.66</td><td align="left" rowspan="1" colspan="1">0.49-0.89</td><td align="left" rowspan="1" colspan="1">
<bold>0.01</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">ccRCC component</td><td align="left" rowspan="1" colspan="1">0.76</td><td align="left" rowspan="1" colspan="1">0.51-1.12</td><td align="left" rowspan="1" colspan="1">0.159</td><td align="left" rowspan="1" colspan="1">0.96</td><td align="left" rowspan="1" colspan="1">0.75-1.22</td><td align="left" rowspan="1" colspan="1">0.72</td><td align="left" rowspan="1" colspan="1">1.63</td><td align="left" rowspan="1" colspan="1">1.06-2.52</td><td align="left" rowspan="1" colspan="1">
<bold>0.03</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Sarcomatoid/rhabdoid differentiation</td><td align="left" rowspan="1" colspan="1">0.88</td><td align="left" rowspan="1" colspan="1">0.61-1.27</td><td align="left" rowspan="1" colspan="1">0.493</td><td align="left" rowspan="1" colspan="1">0.95</td><td align="left" rowspan="1" colspan="1">0.75-1.20</td><td align="left" rowspan="1" colspan="1">0.69</td><td align="left" rowspan="1" colspan="1">1.33</td><td align="left" rowspan="1" colspan="1">0.88-2.02</td><td align="left" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" colspan="10" rowspan="1">Year of 1L start</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2012-2015</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(ref.)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(ref.)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(ref.)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2016-2019</td><td align="left" rowspan="1" colspan="1">1.62</td><td align="left" rowspan="1" colspan="1">0.87-3.02</td><td align="left" rowspan="1" colspan="1">0.130</td><td align="left" rowspan="1" colspan="1">1.18</td><td align="left" rowspan="1" colspan="1">0.81-1.70</td><td align="left" rowspan="1" colspan="1">0.389</td><td align="left" rowspan="1" colspan="1">1.14</td><td align="left" rowspan="1" colspan="1">0.56-2.33</td><td align="left" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;After 2020</td><td align="left" rowspan="1" colspan="1">1.51</td><td align="left" rowspan="1" colspan="1">0.79-2.91</td><td align="left" rowspan="1" colspan="1">0.214</td><td align="left" rowspan="1" colspan="1">0.90</td><td align="left" rowspan="1" colspan="1">0.61-1.30</td><td align="left" rowspan="1" colspan="1">0.566</td><td align="left" rowspan="1" colspan="1">0.95</td><td align="left" rowspan="1" colspan="1">0.46-1.95</td><td align="left" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" rowspan="1" colspan="1">Time from diagnosis to 1L (years)</td><td align="left" rowspan="1" colspan="1">0.97</td><td align="left" rowspan="1" colspan="1">0.93-1.01</td><td align="left" rowspan="1" colspan="1">0.145</td><td align="left" rowspan="1" colspan="1">0.99</td><td align="left" rowspan="1" colspan="1">0.97-1.01</td><td align="left" rowspan="1" colspan="1">0.416</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.96-1.03</td><td align="left" rowspan="1" colspan="1">0.83</td></tr></tbody></table><table-wrap-foot><fn id="T2Fn1"><p>Bold values denote statistical significance at the <italic toggle="yes">P</italic> &lt; 0.05 level.</p></fn><fn id="T2Fn2"><p>Abbreviations: OS, overall survival; TTF, time to treatment failure; ORR, objective response rate; HR, hazard ratio; BMI, body mass index; 1L, first-line; IMDC, International Metastatic renal cell carcinoma Database Consortium; ccRCC, clear cell renal cell carcinoma.</p></fn></table-wrap-foot></table-wrap><p>Similarly, there was no difference in TTF between either former or current smokers compared to never smokers (HR 0.88, 95% CI 0.74-1.04; <italic toggle="yes">P</italic>&#8197;=&#8197;.12 and 0.93; 95% CI 0.73-1.19; <italic toggle="yes">P</italic>&#8197;=&#8197;.59, respectively) in the multivariable model (<xref rid="T2" ref-type="table">Table 2</xref>).</p><p>After adjusting for potential confounding factors, former smokers had a higher ORR compared to never smokers (OR 1.45; 95% CI 1.06-1.98; <italic toggle="yes">P</italic>&#8197;=&#8197;.02), while current smokers had a similar ORR compared to never smokers (OR 1.07; 95% CI 0.69-1.68; <italic toggle="yes">P</italic>&#8197;=&#8197;.76; <xref rid="T2" ref-type="table">Table 2</xref>).</p><p>Given that the assessment of smoking status was conducted at the time of initial RCC diagnosis rather than at the time of ICI treatment initiation, the possibility of change in smoking status between the time of diagnosis and start of treatment should be considered. To mitigate this potential bias, we performed a sensitivity analysis including exclusively patients (<italic toggle="yes">N</italic>&#8197;=&#8197;628) whose diagnosis and treatment initiation were separated by less than a year. In the multivariable models, results derived from the sensitivity analysis paralleled those observed across the whole cohort (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>). Notably, former and current smokers had similar OS compared to never smokers (HR 0.79, 95% CI 0.57-1.08; <italic toggle="yes">P</italic>&#8197;=&#8197;.14 and 0.99; 95% CI 0.65-1.49; <italic toggle="yes">P</italic>&#8197;=&#8197;.95, respectively), as well as similar TTF (HR 0.83, 95% CI 0.67-1.02; <italic toggle="yes">P</italic>&#8197;=&#8197;.08 and 0.88; 95% CI 0.66-1.18; <italic toggle="yes">P</italic>&#8197;=&#8197;.40, respectively). The ORR was higher in former smokers compared to never smokers (OR 2.10, 95% CI 1.40-3.15; <italic toggle="yes">P</italic>&#8197;&lt;&#8197;.001) while it did not reach statistical significance between current and never smokers (OR 1.71, 95% CI 0.98-2.98; <italic toggle="yes">P</italic>&#8197;=&#8197;.06).</p></sec><sec id="s12"><title>Discussion</title><p>In this retrospective study of patients with mRCC who received first-line ICI-based combinations, OS, TTF, and ORR were compared between never, former, and current smokers after adjusting for potential measured confounders. To our knowledge, this is the first analysis showing that smoking status does not independently impact survival and clinical outcomes in patients receiving first-line ICI-based combinations in a large real-world cohort of patients with mRCC.</p><p>In the context of landmark phase III clinical trials evaluating ICI-based combinations in the first-line mRCC setting, smoking status was not accounted for in the prespecified analyses subgroups. However, in the setting of a post hoc exploratory subgroup analysis, in the JAVELIN renal 101 trial, the benefit derived from avelumab and axitinib for current or former smokers was numerically greater compared to the benefit seen in never smokers (HR 0.58, 95% CI 0.42-0.82; vs 0.69, 95% CI 0.47-1.01, respectively).<sup><xref rid="CIT0010" ref-type="bibr">10</xref></sup></p><p>In the earlier era of vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI) monotherapy as the standard of care for first-line treatment of mRCC, active smoking was associated with worse OS. According to one study using the IMDC database, active smoking was independently associated with a shorter OS in patients with mRCC who received VEGF-TKIs. However, patients who quit smoking prior to the initiation of the treatment had a similar OS to those who never smoked. Furthermore, the intensity of smoking, measured by pack years of exposure, was an independent predictor of OS in patients with mRCC who were treated with VEGF-TKIs.<sup><xref rid="CIT0002" ref-type="bibr">2</xref></sup> Also, another retrospective analysis involving patients with mRCC treated between 1989 and 2007 reported a significant association between smoking and reduced cancer-specific survival and OS.<sup><xref rid="CIT0011" ref-type="bibr">11</xref></sup></p><p>However, in the current era of ICI-based combinations, our findings indicate that patients who were actively smoking at the time of treatment initiation will derive similar benefit from ICI-based combinations, compared to never smokers.</p><p>One study in patients with NSCLC showed that increased smoking per pack years was associated with higher TMB, while an increase in smoking-free months was associated with lower TMB highlighting the potential of smoking history as a surrogate marker for TMB in NSCLC.<sup><xref rid="CIT0012" ref-type="bibr">12</xref></sup> The presence of a high TMB is linked to an augmented quantity of tumor neoantigens showcased on the major histocompatibility complex, thus providing a conduit for immune recognition of the tumor and the subsequent development of an antitumor response.<sup><xref rid="CIT0013" ref-type="bibr">13</xref></sup> Previous studies specifically in mRCC failed to show a correlation between TMB and treatment response in multiple randomized studies.<sup><xref rid="CIT0014" ref-type="bibr">14</xref></sup> Specifically, the biomarker analysis from the Checkmate 214 trial as well as the JAVELIN Renal 101 trial found no significant association between TMB levels and response to treatment or survival outcomes.<sup><xref rid="CIT0015" ref-type="bibr">15</xref>,<xref rid="CIT0016" ref-type="bibr">16</xref></sup> Our findings, combined with these studies, suggest that the determinants of immunogenicity differ between mRCC and other tumors such as NSCLC.</p><p>The influence of smoking on immunotherapeutic response may be modulated by organ-specific physiology. Although smoking has been established to have suppressive and pro-apoptotic impacts on T cells, attributed to reactive oxygen and nitrogen species,<sup><xref rid="CIT0017" ref-type="bibr">17</xref></sup> this effect might be offset by the concurrent inflammation observed in smoking-related lung cancer, as evidenced in prior research on chronic obstructive disease, where smoking is notably linked to inflammation in lungs.<sup><xref rid="CIT0018" ref-type="bibr">18</xref></sup> Comprehensive translational research is needed to explore the influence of smoking on the tumor microenvironment and specific antitumor response within the context of RCC.</p><p>Nevertheless, in the univariate analysis, current smokers still displayed a decreased OS, compared to the other subgroups. It is therefore crucial to include patient counseling on smoking cessation as an integral part of the management of mRCC in patients undergoing treatment with ICI-based combinations. Indeed, smoking cessation reduces the risk of second primary cancers, and the development of new tumors.<sup><xref rid="CIT0019" ref-type="bibr">19</xref></sup> This is especially true considering the improvement of survival outcomes seen among patients with mRCC with standard-of-care ICI-based regimens.<sup><xref rid="CIT0020" ref-type="bibr">20</xref></sup> Furthermore, cessation of smoking following cancer diagnosis leads to a reduction in all-cause mortality compared to the continuation of smoking as well as improvement in overall health and quality of life.<sup><xref rid="CIT0021" ref-type="bibr">21</xref></sup></p><p>The current study presents several limitations. First, it should be noted that this study is retrospective in nature. Second, as pointed out previously, smoking status was determined only at the time of initial RCC diagnosis and not at the commencement of ICI treatment; nevertheless, a sensitivity analysis including only patients with less than a year between diagnosis and start of treatment yielded results consistent with those observed in the broader cohort. Furthermore, the evaluation of the smoking status was based on nonstandardized patient interviews and chart reviews. Additionally, due to the unavailability of data on pack years, it was not possible to evaluate the impact of smoking intensity on patient outcomes. Patients were in part from large academic centers where they might not necessarily be representative of the general patient population. Also, other unmeasured confounders, such as underlying comorbidity and medical conditions, that may impact the likelihood of smoking status and clinical outcomes were not assessed.</p></sec><sec id="s13"><title>Conclusion</title><p>This is the first study to investigate the impact of smoking on clinical outcomes in a large cohort of patients with mRCC who received ICI-based regimens. In contrast to other types of cancer such as NSCLC, our findings reveal no significant association between smoking status at diagnosis and clinical outcomes in patients with mRCC treated with first-line ICI-based combinations. Future translational efforts may help to better elucidate the molecular impact of smoking status on disease characteristics and outcomes among patients with advanced kidney cancer. Meanwhile, patient counseling on tobacco cessation remains a crucial aspect of managing patients with mRCC, as it significantly contributes to reducing all-cause mortality as well as improving overall health and quality of life.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>oyae072_suppl_Supplementary_Material</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oyae072_suppl_supplementary_material.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><sec id="s15"><title>Author contributions</title><p>Conceptualization: Eddy Saad, Georges Gebrael, Toni K. Choueiri. Data curation: Eddy Saad, Georges Gebrael, Karl Semaan, Marc Eid, Ren&#233;e Maria Saliby, Chris Labaki, Nicolas Sayegh, J. Connor Wells, Kosuke Takemura, Matthew Scott Ernst, Audreylie Lemelin, Naveen S. Basappa, Lori A. Wood, Thomas Powles, D. Scott Ernst, Aly-Khan A. Lalani. Data analysis and interpretation: Eddy Saad, Georges Gebrael, Karl Semaan, Marc Eid, Ren&#233;e Maria Saliby, Chris Labaki, Nicolas Sayegh, J. Connor Wells, Kosuke Takemura, Matthew Scott Ernst, Audreylie Lemelin, Naveen S. Basappa, Lori A. Wood, Thomas Powles, D. Scott Ernst, Aly-Khan A. Lalani, Neeraj Agarwal, Wanling Xie, Daniel Y.C. Heng, Toni K. Choueiri. Writing&#8212;original draft: Eddy Saad, Georges Gebrael. Writing&#8212;reviews and editing: Eddy Saad, Georges Gebrael, Karl Semaan, Marc Eid, Ren&#233;e Maria Saliby, Chris Labaki, Nicolas Sayegh, J. Connor Wells, Kosuke Takemura, Matthew Scott Ernst, Audreylie Lemelin, Naveen S. Basappa, Lori A. Wood, Thomas Powles, D. Scott Ernst, Aly-Khan A. Lalani, Neeraj Agarwal, Wanling Xie, Daniel Y.C. Heng, Toni K. Choueiri.</p></sec><sec id="s16"><title>Funding</title><p>None declared.</p></sec><sec sec-type="COI-statement" id="s17"><title>Conflicts of interest</title><p>C.L. reports research funding from Genentech/imCORE. N.B. reports honoraria and consulting/advisory roles from Pfizer, Janssen, Astellas Pharma, Eisai, Ipsen, Merck, Bayer, Takeda, AstraZeneca, Seagen, Bristol Myers Squibb, Roche Canada and EMD Serono, research funding from Ipsen; stock and other ownership interests from illumiSonics, support for attending meetings or travel from Eisai, Ipsen, Johnson &amp; Johnson/Janssen, Pfizer. L.A.W. reports research funding from AstraZeneca (Inst), Pfizer (Inst), Bristol Myers Squibb (Inst) and Merck (Inst); advisory boards with BMS, Merck and AstraZeneca, but no personal financial compensation. T.P. reports honoraria and consulting/advisory roles with Roche/Genentech, Bristol Myers Squibb, and Merck; consulting/advisory role with AstraZeneca and Novartis; research funding from AstraZeneca/MedImmune and Roche/Genentech; and other relationships with Ipsen and Bristol Myers Squibb. B.I.R reports grants or contracts from Pfizer, Hoffman-LaRoche, Incyte, AstraZe neca, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, BMS, Mirati Therapeutics, Merck, Surface Oncology, Aravive, Exelixis, Jannsen, Pionyr, AVEO; consulting fees from BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Merck, Corvus, Surface Oncology, Aravive, Alkermes, Arrowhead, Shionogi, Eisai, Nikang Therapeutics, EUSA, Athenex, Allogene Therapeutics, Debiopharm; support for travel from BMS, Pfizer, Merck; participation on a Data Safety Monitoring Board or Advisory Board (Astra Zeneca); Stock or stock options (PTC Therapeutics). A.K.A.L. reports honoraria: Pfizer, Roche/Genentech, Merck, Novartis, Astellas Pharma, Bayer, Bristol Myers Squibb, Eisai, Ipsen; consulting or advisory role at Eisai, Merck, Ipsen, Pfizer, Roche/Genentech, Bristol Myers Squibb, AbbVie, Janssen, Bayer, Astellas Pharma; research funding from Bristol Myers Squibb (Inst), Novartis (Inst), Roche (Inst), Ipsen (Inst), EMD Serono (Inst), BioCanRx (Inst). N.A. has received honorarium before May 2021 and during his lifetime for consulting to Astellas, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics; and has received research funding during his lifetime (to NA&#8217;s institution) from Arnivas, Astellas, AstraZeneca, Bavarian Nordic, Bayer, Bristol Meyers Squibb, Calithera, Celldex, Clovis, CRISPR Therapeutics, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, Glaxo Smith Kline, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. W.X. reports performing consulting for Convergent Therapeutics, Inc. D.Y.C.H. reports consultancy honoraria (to self) and research funding (to institution) from: BMS, Canada, Ipsen, France, Exelixis, United States, Novartis, Switzerland, Pfizer, United States, Merck, United States, Merck KGA, Eisai, Japan. T.K.C. reports research funding, paid to their institution, from AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Lilly, Merck, Nikang, Novartis, Pfizer, Roche, Sanofi/Aventis, and Takeda; consulting fees from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infiniti, Ipsen, Kanaph, Lilly, Merck, Nikang, Novartis, Nuscan, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, Up-To-Date, and CME events; payment or honoraria for lectures, presentations, manuscript writing, or educational events from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infiniti, Ipsen, Kanaph, Lilly, Merck, Nikang, Novartis, Pfizer, Roche, Sanofi/Aventis, Takeda, Tempest, Up-To-Date, and CME events; support for attending meetings or travel from Eisai, Merck, Exelixis, and Pfizer; patents planned, issued, or pending related to ctDNA and biomarkers of response to immune checkpoint inhibitors (no royalties as of April 12, 2022); participated on a data safety monitoring board or advisory board for Aravive; a leadership or fiduciary role in other board, society, committee, or advocacy group, for KidneyCan (unpaid), committees for American Society of Clinical Oncology, European Society for Medical Oncology, National Comprehensive Cancer Network, and Genitourinary Steering Committee of the National Cancer Institute; stock or stock options from Pionyr, Tempest, Precede Bio, and Osel; and salary and research support from Dana-Farber and Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program 5P30CA006516-56, the Kohlberg Chair at Harvard Medical School, and the Trust Family, Michael Brigham, and Loker Pinard Funds for Kidney Cancer Research at Dana-Farber Cancer Institute. All other authors declare no competing interest.</p></sec><sec sec-type="data-availability" id="s18"><title>Data availability</title><p>The data underlying this article will be shared on reasonable request to the corresponding author.</p></sec><ref-list id="r1"><title>References</title><ref id="CIT0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Campi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rebez</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Klatte</surname><given-names>T</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>Effect of smoking, hypertension and lifestyle factors on kidney cancer&#8212;perspectives for prevention and screening programmes</article-title>. <source>Nat Rev Urol</source>. <year>2023</year>;<volume>20</volume>(<issue>11</issue>):<fpage>669</fpage>-<lpage>681</lpage>. <pub-id pub-id-type="doi">10.1038/s41585-023-00781-8</pub-id><pub-id pub-id-type="pmid">37328546</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kroeger</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>De Velasco</surname><given-names>G</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>Active smoking is associated with worse prognosis in metastatic renal cell carcinoma patients treated with targeted therapies</article-title>. <source>Clin Genitourin Cancer</source>. <year>2019</year>;<volume>17</volume>(<issue>1</issue>):<fpage>65</fpage>-<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/j.clgc.2018.09.006</pub-id><pub-id pub-id-type="pmid">30341028</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>The effect of smoking on the immune microenvironment and immunogenicity and its relationship with the prognosis of immune checkpoint inhibitors in non-small cell lung cancer</article-title>. <source>Front Cell Dev Biol</source>. <year>2021</year>;<volume>9</volume>:<fpage>745859</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2021.745859</pub-id><pub-id pub-id-type="pmid">34660603</pub-id><pub-id pub-id-type="pmcid">PMC8512705</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nagahashi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sato</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yuza</surname><given-names>K</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>Common driver mutations and smoking history affect tumor mutation burden in lung adenocarcinoma</article-title>. <source>J Surg Res</source>. <year>2018</year>;<volume>230</volume>:<fpage>181</fpage>-<lpage>185</lpage>. <pub-id pub-id-type="doi">10.1016/j.jss.2018.07.007</pub-id><pub-id pub-id-type="pmid">30072189</pub-id><pub-id pub-id-type="pmcid">PMC10389245</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Popat</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>SV</given-names></string-name>, <string-name name-style="western"><surname>Scheuer</surname><given-names>N</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>Association between smoking history and overall survival in patients receiving pembrolizumab for first-line treatment of advanced non&#8211;small cell lung cancer</article-title>. <source>JAMA Network Open</source>. <year>2022</year>;<volume>5</volume>(<issue>5</issue>):<fpage>e2214046</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.14046</pub-id><pub-id pub-id-type="pmid">35612853</pub-id><pub-id pub-id-type="pmcid">PMC9133943</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rizvi</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Hellmann</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Snyder</surname><given-names>A</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>Mutational landscape determines sensitivity to PD-1 blockade in non&#8211;small cell lung cancer</article-title>. <source>Science</source>. <year>2015</year>;<volume>348</volume>(<issue>6230</issue>):<fpage>124</fpage>-<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaa1348</pub-id><pub-id pub-id-type="pmid">25765070</pub-id><pub-id pub-id-type="pmcid">PMC4993154</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Desrichard</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kuo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Chowell</surname><given-names>D</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>Tobacco smoking-associated alterations in the immune microenvironment of squamous cell carcinomas</article-title>. <source>J Natl Cancer Inst</source>. <year>2018</year>;<volume>110</volume>(<issue>12</issue>):<fpage>1386</fpage>-<lpage>1392</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djy060</pub-id><pub-id pub-id-type="pmid">29659925</pub-id><pub-id pub-id-type="pmcid">PMC6292793</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Heng</surname><given-names>DYC</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Regan</surname><given-names>MM</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study</article-title>. <source>J Clin Oncol</source>. <year>2009</year>;<volume>27</volume>(<issue>34</issue>):<fpage>5794</fpage>-<lpage>5799</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2008.21.4809</pub-id><pub-id pub-id-type="pmid">19826129</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eisenhauer</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Therasse</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bogaerts</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title>. <source>Eur J Cancer</source>. <year>2009</year>;<volume>45</volume>(<issue>2</issue>):<fpage>228</fpage>-<lpage>247</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id><pub-id pub-id-type="pmid">19097774</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Motzer</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Penkov</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Haanen</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma</article-title>. <source>N Engl J Med</source>. <year>2019</year>;<volume>380</volume>(<issue>12</issue>):<fpage>1103</fpage>-<lpage>1115</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1816047</pub-id><pub-id pub-id-type="pmid">30779531</pub-id><pub-id pub-id-type="pmcid">PMC6716603</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kroeger</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Klatte</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Birkh&#228;user</surname><given-names>FD</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival</article-title>. <source>Cancer</source>. <year>2012</year>;<volume>118</volume>(<issue>7</issue>):<fpage>1795</fpage>-<lpage>1802</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.26453</pub-id><pub-id pub-id-type="pmid">21997347</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ricciuti</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname><given-names>T</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>Association between smoking history and tumor mutation burden in advanced non-small cell lung cancer</article-title>. <source>Cancer Res</source>. <year>2021</year>;<volume>81</volume>(<issue>9</issue>):<fpage>2566</fpage>-<lpage>2573</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-20-3991</pub-id><pub-id pub-id-type="pmid">33653773</pub-id><pub-id pub-id-type="pmcid">PMC8137661</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Havel</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Chowell</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>TA</given-names></string-name></person-group>. <article-title>The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy</article-title>. <source>Nat Rev Cancer</source>. <year>2019</year>;<volume>19</volume>:<fpage>133</fpage>-<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1038/s41568-019-0116-x</pub-id><pub-id pub-id-type="pmid">30755690</pub-id><pub-id pub-id-type="pmcid">PMC6705396</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Labaki</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Saliby</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Bakouny</surname><given-names>Z</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>Emerging biomarkers of response to systemic therapies in metastatic clear cell renal cell carcinoma</article-title>. <source>Hematol Oncol Clin North Am</source>. <year>2023</year>;<volume>37</volume>(<issue>5</issue>):<fpage>937</fpage>-<lpage>942</lpage>. <pub-id pub-id-type="doi">10.1016/j.hoc.2023.05.021</pub-id><pub-id pub-id-type="pmid">37407357</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Motzer</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Choueiri</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>McDermott</surname><given-names>DF</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma</article-title>. <source>J ImmunoTher Cancer</source>. <year>2022</year>;<volume>10</volume>(<issue>3</issue>):<fpage>e004316</fpage>. <pub-id pub-id-type="doi">10.1136/jitc-2021-004316</pub-id><pub-id pub-id-type="pmid">35304405</pub-id><pub-id pub-id-type="pmcid">PMC8935174</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Motzer</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Robbins</surname><given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Powles</surname><given-names>T</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial</article-title>. <source>Nat Med</source>. <year>2020</year>;<volume>26</volume>(<issue>11</issue>):<fpage>1733</fpage>-<lpage>1741</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-1044-8</pub-id><pub-id pub-id-type="pmid">32895571</pub-id><pub-id pub-id-type="pmcid">PMC8493486</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hernandez</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Morrow</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Velasco</surname><given-names>C</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>Effects of cigarette smoke extract on primary activated T cells</article-title>. <source>Cell Immunol</source>. <year>2013</year>;<volume>282</volume>(<issue>1</issue>):<fpage>38</fpage>-<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellimm.2013.04.005</pub-id><pub-id pub-id-type="pmid">23665673</pub-id><pub-id pub-id-type="pmcid">PMC3676722</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hodge</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Nairn</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Holmes</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Reynolds</surname><given-names>PN</given-names></string-name>, <string-name name-style="western"><surname>Hodge</surname><given-names>S.</given-names></string-name></person-group><article-title>Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjects</article-title>. <source>Clin Exp Immunol</source>. <year>2007</year>;<volume>150</volume>(<issue>1</issue>):<fpage>22</fpage>-<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2249.2007.03451.x</pub-id><pub-id pub-id-type="pmid">17614970</pub-id><pub-id pub-id-type="pmcid">PMC2219288</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Phua</surname><given-names>ZJ</given-names></string-name>, <string-name name-style="western"><surname>MacInnis</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Jayasekara</surname><given-names>H.</given-names></string-name></person-group><article-title>Cigarette smoking and risk of second primary cancer: a systematic review and meta-analysis</article-title>. <source>Cancer Epidemiol</source>. <year>2022</year>;<volume>78</volume>:<fpage>102160</fpage>. <pub-id pub-id-type="doi">10.1016/j.canep.2022.102160</pub-id><pub-id pub-id-type="pmid">35430427</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Motzer</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>McDermott</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Escudier</surname><given-names>B</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma</article-title>. <source>Cancer</source>. <year>2022</year>;<volume>128</volume>(<issue>11</issue>):<fpage>2085</fpage>-<lpage>2097</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.34180</pub-id><pub-id pub-id-type="pmid">35383908</pub-id><pub-id pub-id-type="pmcid">PMC9543316</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lowy</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Fiore</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Willis</surname><given-names>G</given-names></string-name></person-group>, <etal>et al</etal>. <article-title>Treating smoking in cancer patients: an essential component of cancer care&#8212;the new national cancer institute tobacco control monograph</article-title>. <source>JCO Oncol Pract</source>. <year>2022</year>;<volume>18</volume>(<issue>12</issue>):<fpage>e1971</fpage>-<lpage>e1976</lpage>. <pub-id pub-id-type="doi">10.1200/OP.22.00385</pub-id><pub-id pub-id-type="pmid">36343305</pub-id><pub-id pub-id-type="pmcid">PMC10166433</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>